Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 2/20 | 0.54 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.54 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.43 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965096 | 1.00 | IP6K1 (0.54) | IP6K1IP6K3IP6K2CSF1RKDR | |
| SCHEMBL5552423 | 0.79 | CSF1R (0.45) | IP6K1IP6K3IP6K2CSF1RKDR | |
| SCHEMBL5552420 | 0.79 | CSF1R (0.45) | IP6K1IP6K3IP6K2CSF1RKDR | |
| SCHEMBL5554548 | 0.79 | EGFR (0.43) | IP6K1IP6K3IP6K2CSF1RKDR | |
| SCHEMBL5554550 | 0.79 | EGFR (0.43) | IP6K1IP6K3IP6K2CSF1RKDR | |
| SCHEMBL2774221 | 0.74 | KMT2A (0.65) | KDM4EKMT2ASMN1; SMN2TTRAPP | |
| SCHEMBL2774223 | 0.74 | KMT2A (0.65) | KDM4EKMT2ASMN1; SMN2TTRAPP | |
| SCHEMBL7086909 | 0.73 | ALOX5 (0.66) | KDM4EKMT2ASMN1; SMN2TTRAPP | |
| SCHEMBL7086903 | 0.73 | ALOX5 (0.66) | KDM4EKMT2ASMN1; SMN2TTRAPP | |
| SCHEMBL7673022 | 0.73 | KDM4E (0.62) | IP6K1IP6K3IP6K2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896451-A2 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2007-03-29 | — | — | US | disclosed |
| WO-2006129168-A2 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-1575592-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040254204-A1 | Bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| WO-2004054585-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | IP6K1 3038/4885IP6K3 2408/4885IP6K2 3683/4885 |
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | UGT1A1, CCNA1, UGT1A3 | IP6K1 3031/4885IP6K3 2969/4885IP6K2 3428/4885 |
| US-20040254204-A1 | Bicyclic derivatives for the treatment of abnormal cell growth | UGT1A1, UGT1A3, UGT2B17 | IP6K1 2031/4885IP6K3 2065/4885IP6K2 2410/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | IP6K1 3038/4885IP6K3 2408/4885IP6K2 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.